Specialty Chemicals

DAYANG BIOTECH

DAYANG BIOTECH released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 278.13 M, actual EPS CNY 0.38

DAYANG BIOTECH released FY2025 earnings on April 27 After-Market (BJT), actual revenue CNY 1.045 B, actual EPS CNY 1.2134

DAYANG BIOTECH released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 298.13 M, actual EPS CNY 0.2323

DAYANG BIOTECH FY2026 Q1 Earnings Release on April 28 After-Market (BJT)

DAYANG BIOTECH to Release FY2025 Earnings on April 28 After-Market (BJT)

DAYANG BIOTECH released FY2025 Q3 earnings on October 17 After-Market (BJT), actual revenue CNY 248 M, actual EPS CNY 0.3634

DAYANG BIOTECH released FY2025 9-month earnings on October 17 After-Market (BJT), actual revenue CNY 747.31 M, actual EPS CNY 0.9845

DAYANG BIOTECH FY2025 Q3 Earnings Release on October 21 After-Market BJT

DAYANG BIOTECH released FY2025 Q2 earnings on August 25 After-Market BJT, actual revenue CNY 250.34 M, actual EPS CNY 0.2604

DAYANG BIOTECH released FY2025 Semi-Annual Earnings on August 25 After-Market BJT, actual revenue CNY 499.31 M, actual EPS CNY 0.6212

DAYANG BIOTECH to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Shanghai Xinzhichun Semiconductor Material Co., Ltd. Established

Ocean Biochemicals Anticipates Net Profit of 42-52 Million Yuan in H1 2025

Ocean Bio's Product Prices Fluctuate Within Reasonable Range

DAYANG BIOTECH released FY2024 Q4 earnings on April 21, 2025 (BJT) with actual revenue of CNY 238.16 M and EPS of CNY 0.1557

DAYANG BIOTECH released FY2024 Annual Earnings on April 21, 2025 (BJT) with actual revenue of CNY 909.96 M and EPS of CNY 0.7769

Ocean Biochemistry Announces 2024 Financial Results and Dividends

Ocean Biopharmaceuticals Q1 2025 Net Profit Up 73.44%

DAYANG BIOTECH released FY2025 Q1 earnings on April 21 Pre-Market BJT, actual revenue CNY 248.97 M, actual EPS CNY 0.3607

DAYANG BIOTECH to Release FY2025 Q1 Earnings on April 22 Pre-Market BJT

003017

DAYANG BIOTECH released its Q3 2025 report, with operating revenue for the first three quarters amounting to 747 million yuan, a year-on-year increase of 11.24%. The net profit attributable to the parent company was 80.0366 million yuan, a year-on-year increase of 56.12%. The net profit after deducting non-recurring gains and losses was 74.9836 million yuan, a year-on-year increase of 55.61%. The basic earnings per share were 0.9846 yuan

Zhitong

DAYANG BIOTECH released its performance for the first three quarters, with a net profit attributable to the parent company of 80.366 million yuan, an increase of 56.12%

DAYANG BIOTECH expects the net profit attributable to the parent company for the first three quarters of 2025 to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%. The net profit after deducting non-recurring gains and losses is expected to be between 67 million yuan and 82 million yuan, a year-on-year increase of 39.04% to 70.17%. The growth in performance is mainly driven by market demand, with sales and prices of the main products, potassium carbonate and veterinary raw materials, rising, leading to an increase in gross profit margin

DAYANG BIOTECH issued a preliminary increase, expecting the net profit attributable to the parent company for the first three quarters to be between 74 million yuan and 90 million yuan, a year-on-year increase of 44.35% to 75.56%

600486

600586

600389

002258

The A-share chemical and chemical engineering sector fluctuated and strengthened, JJKJ hit the daily limit, DAYANG BIOTECH rose over 5%, JSAC, LIER CHEMICAL, and Yangnong Chemical followed suit

Yangnong Chemical

JJKJ

JSAC

LIER CHEMICAL

On August 25th, DAYANG BIOTECH disclosed its semi-annual report, stating that the company achieved operating revenue of 499 million yuan in the first half of the year, a year-on-year increase of 14.20%; the net profit attributable to shareholders of the listed company was 50.5056 million yuan, compared to 31.4363 million yuan in the same period last year, a year-on-year increase of 60.66%; the basic earnings per share were 0.6212 yuan

DAYANG BIOTECH: In the first half of the year, the net profit attributable to the parent company was 50.5056 million yuan, a year-on-year increase of 60.66%

DAYANG BIOTECH announced that the Zhejiang Regulatory Bureau has taken corrective measures against shareholder Yang Xingli and his concerted actors. After Yang Xingli held more than 5% of the shares, his concerted actors failed to promptly notify the company of their 1% increase in shareholding, violating relevant acquisition management regulations

DAYANG BIOTECH: The Zhejiang Regulatory Bureau has taken corrective measures against the company's shareholder Yang Xingli and his concerted actors

300149

300696

301511

300476

This week, 125 listed companies disclosed institutional research minutes, with nearly 40% of stocks achieving positive returns. Defu Technology and VGT rose more than 20%, while ChemPartner, DAYANG BIOTECH, ALD, and 7 other stocks rose more than 10%. The median price change of the surveyed stocks was -1.51%

Wallstreetcn

ChemPartner

Defu Technology

The research enthusiasm for star companies is high, and leading enterprises frequently release positive signals

301000

Institutions predict that 7 PEEK material concept stocks are expected to see annual performance growth. PEEK materials, due to their excellent biocompatibility, high-temperature resistance, corrosion resistance, and high mechanical strength, have become core materials for humanoid robot joints and transmission systems. According to statistics from Securities Times·Data Treasure, PEEK material concept stocks have averaged a 31.95% increase this year, with Weike Technology, SHANGHAI HAJIME ADVANCED MATERIAL TECHNOLOGY, and DAYANG BIOTECH seeing increases of over 50%. Multiple institutions unanimously predict that these concept stocks will see annual performance growth

SHANGHAI HAJIME ADVANCED MATERIAL TECHNOLOGY

Institutions predict that the annual performance of 7 PEEK material concept stocks is expected to grow

DAYANG BIOTECH stated on the interactive platform that the product prices this year have mainly been determined by factors such as market supply and demand, and raw material costs, with price fluctuations remaining within a reasonable range. The company currently maintains stable raw material supply and production operations. The 800t/a hydrochloride amipriptyline relocation and expansion technical transformation project is in the construction phase. As the scale farming and centralized breeding model gradually solidifies, market demand is steadily increasing

DAYANG BIOTECH: The market demand for Amipriline Hydrochloride is gradually increasing

DAYANG BIOTECH announced its 2025 equity incentive plan, intending to grant no more than 994,100 restricted shares to 7 incentive recipients, with a grant price of RMB 12.34 per share. The plan is valid from the date of completion of the grant registration until the restricted shares are released from restrictions or repurchased and canceled, lasting no more than 36 months

DAYANG BIOTECH plans to grant no more than 994,100 restricted shares

002915

301131

301076

PEEK material concept performs brilliantly, with stocks such as SELON, SINO—HIGH, ZXFC, and DAYANG BIOTECH hitting the limit up

ZXFC

SELON

SINO—HIGH

PEEK material concept performs outstandingly, with stocks like SELON hitting the limit up

DAYANG BIOTECH(003017.SZ)